TGFB1 and osteogenesis imperfecta: Considering the limitations that anti-resorptive therapies present, this review has focused mainly io the anabolic ones, which induce bone formation by targeting signaling pathways altered in OI (TGF-β superfamily or ER stress) or by inducing osteoblast differentiation and activity (cellular therapies or the Wnt signaling pathway).